Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 8 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10077444

    Compositions and methods for inhibiting expression of the LECT2 gene

    Alnylam Pharmaceuticals, Inc. · Granted Sep 18, 2018 · Expires Sep 13, 2038

    granted
  2. US 10060921

    Methods of treating transthyretin (TTR) mediated amyloidosis

    Alnylam Pharmaceuticals, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted
  3. US 10030244

    Serpina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted
  4. US 9999673

    PEGylated lipids and their use for drug delivery

    Alnylam Pharmaceuticals, Inc. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  5. US 9982263

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted
  6. US 9970006

    Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

    Alnylam Pharmaceuticals, Inc. · Granted May 15, 2018 · Expires May 10, 2038

    granted
  7. US 9963700

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted May 8, 2018 · Expires May 3, 2038

    granted
  8. US 9957507

    Compositions and methods for inhibiting expression of mutant EGFR gene

    Alnylam Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  9. US 9944671

    Compositions and methods directed to treating liver fibrosis

    Alnylam Pharmaceuticals, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  10. US 9932593

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  11. US 9902955

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 27, 2018 · Expires Feb 22, 2038

    granted
  12. US 9868950

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted
  13. US 9867882

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted
  14. US 9850488

    Complement component C5 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 26, 2017 · Expires Dec 21, 2037

    granted
  15. US 9822365

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 21, 2017 · Expires Nov 16, 2037

    granted
  16. US 9796974

    Modified RNAi agents

    Alnylam Pharmaceuticals, Inc. · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted
  17. US 9783806

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted
  18. US 9771591

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  19. US 9708615

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted
  20. US 9701963

    Complement component C5 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 11, 2017 · Expires Jul 6, 2037

    granted
  21. US 9687448

    Nucleic acid lipid particle formulations

    Alnylam Pharmaceuticals, Inc. · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted
  22. US 9682922

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  23. US 9631193

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2017 · Expires Apr 20, 2037

    granted
  24. US 9587240

    Compositions and methods for inhibiting expression of a target gene

    Alnylam Pharmaceuticals, Inc. · Granted Mar 7, 2017 · Expires Mar 2, 2037

    granted